[¹⁷⁷Lu]Lu-EDTMP -a bone pain palliating agent: pharmacokinetics, biodistribution, safety profile and clinical evaluation in osseous metastatic patients.

ABSTRACT:

Background

[¹⁷⁷Lu]Lu-EDTMP has emerged as a promising radiopharmaceutical for the palliation of pain caused by osseous metastases. This phase I/II study comprehensively evaluate the pharmacokinetics, biodistribution, clinical efficacy, and safety profile of [¹⁷⁷Lu]Lu-EDTMP, in patients with skeletal metastases from breast and prostate cancer.

Methods

A total of 27 patients with skeletal metastases were included in the study. Pharmacokinetics and biodistribution were analyzed in 17 patients through whole-body gamma camera imaging and quantification at multiple time points. Clinical efficacy and safety were evaluated in 18 patients receiving either low (1.3 GBq) or high (2.6 GBq) administered activity. Pain palliation was assessed using visual analog scal

SUBMITTER: Saeed S 

PROVIDER: S-EPMC12316809 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature